NeuroMetrix reports Q4 EPS ($1.43) vs (73c) last year

Reports Q4 revenue $1.317M vs $1.847M last year. “Quell Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging. We also introduced direct-to-patient telemedicine capabilities, direct to physician sales, and reimbursement at select Veterans Administration facilities,” said Shai Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “Also, during Q4 2023 we achieved our goal of filing a premarket notification with the FDA to market Quell for chemotherapy induced peripheral neuropathy. Quell received FDA breakthrough device designation for this indication in January 2022.”